Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–35 of 11 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Grade 3a Follicular Lymphoma Clear all

Active, not recruiting Phase 2 Interventional Results available

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

NCT02446457

View directory record Official record

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
Interventions: Laboratory Biomarker Analysis, Lenalidomide, Pembrolizumab, Rituximab; Other · Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Mar 8, 2026 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 1Phase 2 Interventional Results available

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

NCT03010358

View directory record Official record

Conditions: Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
Interventions: Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab, Pharmacological Study; Drug · Other · Biological
Lead sponsor: Alexey Danilov, MD; Other
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Source: ClinicalTrials.gov public record

Updated Aug 7, 2023 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 1Phase 2 Interventional Results available

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

NCT00670358

View directory record Official record

Conditions: Lymphoma
Interventions: pegfilgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, lenalidomide, prednisone, vincristine sulfate, polymorphism analysis, laboratory biomarker analysis; Biological · Drug · Genetic + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years

Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Source: ClinicalTrials.gov public record

Updated Jan 9, 2025 · Synced May 21, 2026, 6:33 PM EDT

Active, not recruiting Phase 3 Interventional Results available

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052

View directory record Official record

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma
Interventions: tafasitamab, rituximab, lenalidomide, placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older

Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 38
States / cities: Concord, California • Greenbrae, California • Pasadena, California + 33 more

Source: ClinicalTrials.gov public record

Updated Dec 21, 2025 · Synced May 21, 2026, 6:33 PM EDT

Active, not recruiting Phase 2 Interventional

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

NCT05451810

View directory record Official record

Conditions: Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
Interventions: Epcoritamab; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older

Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 70
States / cities: Mobile, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 60 more

Source: ClinicalTrials.gov public record

Updated Jan 23, 2025 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 2 Interventional Results available

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

NCT02532257

View directory record Official record

Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, CD20 Positive, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions: Ibrutinib, Laboratory Biomarker Analysis, Lenalidomide, Rituximab; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Sep 23, 2024 · Synced May 21, 2026, 6:33 PM EDT

Terminated Phase 2 Interventional Results available

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT04659044

View directory record Official record

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions: Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human, Venetoclax; Drug · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older

Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Sioux City, Iowa • Ann Arbor, Michigan • St Louis, Missouri + 2 more

Source: ClinicalTrials.gov public record

Updated Sep 18, 2024 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 2 Interventional Results available

Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

NCT02871219

View directory record Official record

Conditions: Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Bulky Disease, Fatigue, Fever, Grade 3a Follicular Lymphoma, Night Sweats, Splenomegaly, Weight Loss
Interventions: Lenalidomide, Obinutuzumab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Jun 7, 2025 · Synced May 21, 2026, 6:33 PM EDT

Completed Phase 2 Interventional Results available

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

NCT04205409

View directory record Official record

Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Nivolumab; Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Source: ClinicalTrials.gov public record

Updated May 11, 2026 · Synced May 21, 2026, 6:33 PM EDT

Recruiting Phase 2 Interventional

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

NCT06453044

View directory record Official record

Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mosunetuzumab, Polatuzumab Vedotin, Positron Emission Tomography, Questionnaire Administration; Procedure · Biological · Drug + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older

Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Source: ClinicalTrials.gov public record

Updated Sep 23, 2025 · Synced May 21, 2026, 6:33 PM EDT

Active, not recruiting Phase 2 Interventional

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

NCT03198026

View directory record Official record

Conditions: Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma, Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Nodal Marginal Zone Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Nodal Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-hodgkin Lymphoma, Stage II Splenic Marginal Zone Lymphoma, Stage III Splenic Marginal Zone Lymphoma, Stage IV Splenic Marginal Zone Lymphoma
Interventions: Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older

Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Feb 18, 2026 · Synced May 21, 2026, 6:33 PM EDT